Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jul 31, 2018
TOKYO & KENILWORTH, N.J., July 31, 2018 – Eisai Co., Ltd. and Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration...
Jun 3, 2018-- First presentation of LENVIMA/KEYTRUDA data in patients with unresectable hepatocellular carcinoma (HCC), which aims to be the first systemic combination of a TKI and immunotherapy for these patients, as well as squamous cell carcinoma of the head and neck (SCCHN)Eisai Inc. and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from presentations of new data and analyses of LENVIMA® (lenvatinib), an orally...
May 24, 2018Eisai Inc. and Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has extended the action date for the...
-
May 17, 2018- Data highlights continued investigation of LENVIMA as monotherapy and in combination with Merck's KEYTRUDA across multiple cancer types under global collaboration to co-develop and co-commercialize LENVIMA
Eisai Inc. today announced the presentation of new data and analyses at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting from June 1-5 in Chicago. The data to be presented...
-
Feb 15, 2018
Eisai Inc. announced today that the positive results of a Phase 3 study (REFLECT study, Study 304) of its in-house discovered and developed anticancer agent lenvatinib mesylate (marketed as...